Close

Biomatters bumps MD up to CEO

Biomatters bumps MD up to CEO
Genomics software company Biomatters has appointed former managing director Dr Brett Ammundsen as chief executive to lead the company as genomics progresses from research into new clinical and consumer applications.

Genomics software company Biomatters has appointed former managing director Dr Brett Ammundsen as chief executive to lead the company as genomics progresses from research into new clinical and consumer applications.

Brett AmmundsenWith a career in science and several peer-reviewed publications and patents to his name, Ammundsen sees an important role for providers of bioinformatics tools ahead.

“There is a lot of excitement about the $1000 genome, but sequencing entire genomes at a low cost generates an enormous amount of data which requires expert interpretation. To truly realise the promise of genomics, we need smart interfaces allowing clinicians and consumers to connect to the knowledge associated with the genomic data, and make real world decisions with confidence."

Ammundsen is a strong supporter of the vision of personal genomics and is participating in the 23andMe pilot exome project.

“There is nothing quite like looking at your own genomic data,” he said. “It’s an insight into the lineage of your past as well as your potential future."

Biomatters chairman Greg Casagrande said Ammundsen was seasoned in the commercialisation of leading-edge science.

“The appointment of Brett comes at a time when the genomics industry and our customers are experiencing a game-changing revolution in both genome sequencing and computing technologies."